1. Home
  2. TPCS vs RNTX Comparison

TPCS vs RNTX Comparison

Compare TPCS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TPCS
  • RNTX
  • Stock Information
  • Founded
  • TPCS 1956
  • RNTX 2001
  • Country
  • TPCS United States
  • RNTX United States
  • Employees
  • TPCS N/A
  • RNTX N/A
  • Industry
  • TPCS Metal Fabrications
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TPCS Industrials
  • RNTX Health Care
  • Exchange
  • TPCS Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • TPCS 42.6M
  • RNTX 40.3M
  • IPO Year
  • TPCS N/A
  • RNTX N/A
  • Fundamental
  • Price
  • TPCS $3.74
  • RNTX $1.45
  • Analyst Decision
  • TPCS
  • RNTX
  • Analyst Count
  • TPCS 0
  • RNTX 0
  • Target Price
  • TPCS N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • TPCS 29.5K
  • RNTX 37.5K
  • Earning Date
  • TPCS 04-08-2025
  • RNTX 08-13-2025
  • Dividend Yield
  • TPCS N/A
  • RNTX N/A
  • EPS Growth
  • TPCS N/A
  • RNTX N/A
  • EPS
  • TPCS N/A
  • RNTX N/A
  • Revenue
  • TPCS $33,154,058.00
  • RNTX N/A
  • Revenue This Year
  • TPCS N/A
  • RNTX N/A
  • Revenue Next Year
  • TPCS N/A
  • RNTX N/A
  • P/E Ratio
  • TPCS N/A
  • RNTX N/A
  • Revenue Growth
  • TPCS 8.71
  • RNTX N/A
  • 52 Week Low
  • TPCS $2.05
  • RNTX $1.33
  • 52 Week High
  • TPCS $4.42
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • TPCS 54.79
  • RNTX N/A
  • Support Level
  • TPCS $3.45
  • RNTX N/A
  • Resistance Level
  • TPCS $3.85
  • RNTX N/A
  • Average True Range (ATR)
  • TPCS 0.23
  • RNTX 0.00
  • MACD
  • TPCS 0.00
  • RNTX 0.00
  • Stochastic Oscillator
  • TPCS 62.32
  • RNTX 0.00

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: